Hansa Biopharma: Q3 Launch and Genetic exploratory progress - Redeye

Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.

Länk till analysen i sin helhet: https://www.redeye.se/research/858658/hansa-biopharma-q3-launch-and-genetic-exploratory-progress?utm_source=finwire&utm_medium=RSS